The end of life with PD can be well-lived The neurologist's role Managing Parkinson disease (PD) in its early stages is satisfying to both patients and clinicians because patients benefit considerably from treatments that support independent living 1 ; but as the illness progresses, management is more challenging. Dementia, hallucinosis, advanced motor, autonomic, and postural instability, and complications of prolonged symptomatic treatment bring dependence and increased risk of life-threatening injuries including hip fracture. Quality clinical care requires anticipation and planning from all involved with many people requiring nursing home and end-of-life care.
The sheer scale of providing care to those with advanced PD is highlighted in an article focusing on end-of-life care in this issue of Neurology ® . 2 The authors' analysis provides valuable insights into utilization of nursing home and hospice services by patients with PD, underscoring the role of neurologists. The report should inform counseling provided to people with PD and their caregivers, and sets challenges for physicians, researchers, health care planners, and long-term care facilities (LTCFs).
Safarpour et al. 2 identified more than 450,000 Medicaid beneficiaries older than 65 years who had a recorded diagnosis of PD in 2002. Of these, 24% were receiving nursing home care. Almost 85% of those residing in LTCFs in 2002 died between 2003 and 2005, and 54% of the deceased had received hospice care. Nursing home patients were older, more often women, and had more comorbidities than patients with PD in the community. Sixtyfive percent had dementia compared with 29% in the community, and twice as many had a recent hip fracture. Each condition predicted admission to LTCFs after adjustment for other factors.
African Americans comprised 5.7% of the identified PD cases in nursing homes and 4.7% in the community. While African Americans are generally less likely to reside in a nursing home, 3 those with PD were 34% more likely to receive nursing home care, after adjusting for sociodemographic characteristics and comorbidity. Explanations for this difference could include an underlying difference in disease severity, disparities in treatment of PD 4-6 possibly leading to avoidable LTCF admissions, or unaccounted clinical and sociodemographic factors. The difference could be explained by delayed diagnosis of PD in African Americans, thus underestimating the community prevalence of PD. Late diagnosis may worsen survival and increase the risk of hip fractures. 7 One-third of the nursing home patients with PD received neurology care as outpatients and these patients were not representative of the larger LTCF cohort. They were less likely to have dementia, hip fractures, congestive cardiac failure, ischemic heart disease, or cerebrovascular disease. Despite the strength of this association, we cannot conclude that the effect is causative. These patients may simply be healthy enough to leave the nursing home and attend a neurologist appointment, in contrast to their sicker peers. The one-third of LTCF patients receiving neurologist care were twice as likely to receive hospice care at the end of their lives, which is a possible indicator of higher-quality end-of-life care.
Reliance on clinical features to diagnose PD introduces a risk of error in case ascertainment for any observational study. Safarpour et al. 2 used routinely collected administrative data provided by Medicaid in their analysis. While these data are well-suited to examining health care delivery across large populations, specific caveats apply. A number of validated methods for accurately identifying PD in Medicaid and related databases exist, [8] [9] [10] as contrasted with selfreport (e.g., "Have you ever been told you had Parkinson disease?"). Self-reporting could capture people with suspected PD, Parkinson-plus syndromes, and secondary parkinsonism as well as other neurologic conditions, 10 and any such misclassification could inflate PD prevalence. One longitudinal populationbased study reported that only 40% of self-reported PD cases had typical neuropathology findings in a small postmortem sample, 10 although another study suggested greater specificity of self-report in a relatively young PD cohort when compared against clinical assessment.
9 Safarpour et al. 2 identified their PD cases using the ICD-9 332 diagnostic code from physician/ carrier claims, excluding beneficiaries with a concomitant diagnosis of Parkinson-plus syndrome. Against the reference of self-report, the sensitivity of PD diagnostic codes is around 66%; however, the specificity of PD identification by Safarpour et al. 2 is expected to be 99% or better. 8, 9 Whether or not missed cases of PD were systematically different in their demographic characteristics or outcomes is unknown, and we do not know how relevant the reported 2002-2005 data are to practice in 2015.
Given the early clinical responsiveness of PD, it is natural to overlook some harsh facts: we are managing a chronic and progressive condition for which palliative care begins at the first consultation, with a large proportion of patients with PD destined to reside in nursing homes.
We might assume that most patients with PD would receive a benefit from hospice care or at least end-of-life planning. Safarpour et al. 2 suggest that tens of thousands of patients with PD would benefit from such care and from improved access to neurologists toward the end of their disease. Here, the association with neurologist ambulatory care should not be mistaken for a causal effect, as this study cannot overcome the selection bias of patients with better responses to therapy or fewer comorbidities enabling transport to outpatient neurologist care. Nonetheless, this report highlights an important role for neurologists at a stage when transport of patients with PD may be less feasible and when changes in specific PD treatment may seem futile. Perhaps increased neurologist awareness of their efficacy in the nursing home setting and emerging use of telemedicine will facilitate better end-of-life care for people with PD.
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